84 212

Cited 19 times in

Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.

Authors
Park, EJ; Choi, KS; Yoo, YH; Kwon, TK
Citation
Anti-cancer drugs, 24(3):260-269, 2013
Journal Title
Anti-cancer drugs
ISSN
0959-49731473-5741
Abstract
Nutlin-3 is a novel small-molecule antagonist of the human homolog of mouse double minute (MDM2) that binds MDM2 in the p53-binding pocket and activates the p53 signaling pathway. In this study, we show that nutlin-3 sensitizes Caki human renal cancer cells, but not normal human skin fibroblast (HSF) cells or human mesangial cells, to TRAIL-mediated apoptosis. Combined treatment with nutlin-3 and TRAIL markedly induces apoptosis in HCT116 cells (p53 wild type), but not in HCT116 p53-/- cells, suggesting that p53 is critical for the sensitizing effect of nutlin-3 on TRAIL-induced apoptosis. Pretreatment with N-acetylcysteine (NAC) significantly inhibited nutlin-3-induced DR5 upregulation and cell death induced by the combined treatment with nutlin-3 and TRAIL, suggesting that reactive oxygen species (ROS) mediate nutlin-3-induced DR5 upregulation, which contributes toward TRAIL-mediated apoptosis. However, the upregulation of the p53-mediated protein p53 upregulated modulator of apoptosis (PUMA) by nutlin-3 is likely to be ROS independent because antioxidants failed to block PUMA upregulation. Interestingly, a combined treatment with NAC and PUMA small interfering RNAs significantly blocks nutlin-3-induced and TRAIL-induced apoptosis. Therefore, the present study shows that nutlin-3 enhances TRAIL-induced apoptosis in human renal cancer cells by ROS-mediated or p53-mediated DR5 upregulation and p53-induced PUMA upregulation. These results may offer a novel therapeutic approach to TRAIL-based cancer therapy.
MeSH terms
Acetylcysteine/pharmacologyApoptosis/*drug effects/physiologyApoptosis Regulatory Proteins/*metabolismCell Line, TumorFibroblasts/drug effects/metabolismGenes, p53HCT116 Cells/drug effectsHumansImidazoles/*pharmacologyKidney Neoplasms/drug therapy/metabolism/pathologyPiperazines/*pharmacologyProto-Oncogene Proteins/*metabolismProto-Oncogene Proteins c-mdm2/*antagonists & inhibitorsReactive Oxygen Species/metabolismReceptors, TNF-Related Apoptosis-Inducing Ligand/*metabolismTNF-Related Apoptosis-Inducing Ligand/metabolism/pharmacologyUp-Regulation/drug effects
DOI
10.1097/CAD.0b013e32835c0311
PMID
23187459
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Biochemistry & Molecular Biology
AJOU Authors
최, 경숙
Full Text Link
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse